
Investors Target ADMA Biologics in Securities Fraud Class Action
A federal class action lawsuit now challenges ADMA Biologics, accusing the company of inflating its financial health through deceptive trade practices between August 9, 2024, and March 25, 2026. The DJS Law Group is currently organizing shareholders who incurred losses during this period to seek potential legal recovery.















/solarbytes/media/media_files/2025/11/21/2025-11-21-sungrow-ny-2025-11-21-16-42-06.jpg)








